Researchers have developed a new targeted nanomedicine that combines chemotherapy and immunotherapy to treat Colorectal Cancer. The therapy uses irinotecan loaded into nanoparticles coated with molecules that specifically bind to CD44v6, a protein commonly found on metastatic colorectal cancer cells. This approach allows the chemotherapy to reach tumors more precisely while boosting the immune system with anti-PD-L1 therapy.
In lab tests using 3D tumor models, cancer cells with high CD44v6 levels absorbed more nanoparticles, and the treatment reprogrammed the immune environment by reducing pro-tumor macrophages and increasing immune-activating signals. In mouse models, the combination therapy reduced tumor size by over 50% compared to controls, increased the number of T-cells in tumors, and caused fewer side effects than standard irinotecan treatment.
The study suggests that CD44v6-targeted nanomedicine can “prime” tumors for immunotherapy, making the immune system more effective at attacking cancer. Future research will explore how to optimize nanoparticle delivery for larger, more resistant tumors.